17 analysts have expressed a variety of opinions on Johnson & Johnson JNJ over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 13 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 6 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 4 | 3 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Johnson & Johnson, presenting an average target of $193.94, a high estimate of $215.00, and a low estimate of $150.00. This current average has decreased by 0.6% from the previous average price target of $195.12.
Investigating Analyst Ratings: An Elaborate Study
The perception of Johnson & Johnson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $178.00 | $175.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $215.00 | $215.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Narumi Nakagiri | Daiwa Capital | Lowers | Neutral | $150.00 | $160.00 |
| Chris Shibutani | Goldman Sachs | Lowers | Neutral | $155.00 | $160.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $175.00 | $175.00 |
| Joshua Jennings | TD Cowen | Lowers | Buy | $185.00 | $195.00 |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $169.00 | $167.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Johnson & Johnson. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Johnson & Johnson compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Johnson & Johnson's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Johnson & Johnson's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Johnson & Johnson analyst ratings.
All You Need to Know About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson: A Financial Overview
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Johnson & Johnson's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.31%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 6.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Johnson & Johnson's ROA excels beyond industry benchmarks, reaching 2.65%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
The Significance of Analyst Ratings Explained
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
